Oral diabetes medication monotherapy and short-term mortality in individuals with type 2 diabetes and coronary artery disease.
Sridharan RaghavenWenhui G LiuDavid R SaxonGary K GrunwaldThomas M MaddoxJane E B ReuschSeth A BerkowitzLiron CaplanPublished in: BMJ open diabetes research & care (2018)
Sulfonylurea use was common (nearly one-third of those taking medications) and was associated with increased 2-year mortality in individuals with obstructive CAD. The significance of the association between sulfonylurea use and mortality was attenuated in fully adjusted survival models. Caution with sulfonylurea use may be warranted for patients with well-controlled diabetes and CAD, and metformin or newer diabetes medications with cardiovascular safety data could be considered as alternatives when individualizing therapy.
Keyphrases
- coronary artery disease
- cardiovascular events
- type diabetes
- cardiovascular disease
- glycemic control
- risk factors
- percutaneous coronary intervention
- coronary artery bypass grafting
- healthcare
- stem cells
- clinical trial
- electronic health record
- emergency department
- randomized controlled trial
- bone marrow
- acute coronary syndrome
- mesenchymal stem cells
- open label
- artificial intelligence
- combination therapy
- left ventricular
- ejection fraction
- smoking cessation
- replacement therapy
- weight loss
- data analysis
- aortic stenosis